Prosigna Score and 10-Year Distant Recurrence in Women Receiving Endocrine Therapy for Early Breast Cancer


Key Points

  • Risk of recurrence score identified patients at lower and higher risk of recurrence among both node-negative and node-positive patients.
  • Luminal B tumors were associated with higher risk of recurrence vs luminal A tumors.

In a Danish study reported in the Journal of Clinical Oncology, Lænkholm and colleagues found that the PAM50-based Prosigna risk of recurrence score could identify lower risk of 10-year distant recurrence in subgroups of postmenopausal women who received 5 years of endocrine therapy alone for hormone receptor–positive early breast cancer.

Study Details

The study involved data from 2,558 patients with hormone receptor–positive, HER2-negative disease from the Danish Breast Cancer Cooperative Group database diagnosed from 2000 through 2003. Of these, 1,395 patients had node-positive disease. All patients had received 5 years of endocrine therapy.

The prognostic value of risk of recurrence score for distant recurrence was assessed.

Risk Levels

Median follow-up for recurrence was 9.2 years. Among patients with one to three positive nodes, 10-year distant recurrence risk was 3.5% among 359 patients classified as low risk of recurrence, compared with 10-year risk of 22.1% among 648 patients with high risk of recurrence (P < .001). Among node-negative patients, 10-year risk of distant recurrence was 5.0% among those with low risk of recurrence and 17.8% among those with high risk of recurrence (P < .001). Patients with luminal B tumors (n = 947) had 10-year risk of 18.4%, compared with 7.6% among those with luminal A tumors (n = 1,474; P < .001).

The investigators concluded, “Prosigna [risk of recurrence] score improved the prediction of outcome in this nationwide Danish population. In a real-world setting, Prosigna can reliably identify node-negative patients and a significant proportion of patients with one to three positive nodes who can be spared treatment with adjuvant chemotherapy.”

The study was supported by Nanostring Technologies.

Anne-Vibeke Lænkholm, MD, of the Department of Surgical Pathology, Zealand University Hospital, Denmark, was the corresponding author for the Journal of Clinical Oncology article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.